Ticker Details
Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its products portfolio includes Glybera, TV-45070.
IPO Date:	November 5, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.88B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.52 | 2.56%
Avg Daily Range (30 D):	$1.16 | 1.77%
Avg Daily Range (90 D):	$1.01 | 1.69%

Institutional Daily Volume
Avg Daily Volume:	.32M
Avg Daily Volume (30 D):	.63M
Avg Daily Volume (90 D):	.98M

Trade Size
Avg Trade Size (Sh.):	78
Avg Trade Size (Sh.) (30 D):	48
Avg Trade Size (Sh.) (90 D):	60

Institutional Trades
Total Institutional Trades:	3,329
Avg Institutional Trade:	$2.05M
Avg Institutional Trade (30 D):	$3.61M
Avg Institutional Trade (90 D):	$3.7M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.94M
Avg Closing Trade (30 D):	$6.92M
Avg Closing Trade (90 D):	$10.49M
Avg Closing Volume:	69.52K

News

Jun 10, 2026 @ 5:00 PM Metastatic Prostate Cancer Market Set for Robust G... Source: Delveinsight

Apr 19, 2026 @ 10:00 PM Xenon Presents Azetukalner Phase 3 X-TOLE2 Study R... Source: Xenon Pharmaceuticals Inc.

Mar 27, 2026 @ 11:03 PM Xenon Pharma Stock Up 55% as Insider Sells $78K in... Source: Jonathan Ponciano

Mar 11, 2026 @ 2:39 AM Xenon Pharmaceuticals Announces Pricing of Upsized... Source: Na

Feb 23, 2026 @ 3:18 PM Spyre Therapeutics Stock Surges This Past Year as ... Source: Jonathan Ponciano

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-4.74	$-1.11	$-1.17
Diluted EPS	$-4.74	$-1.11	$-1.17
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-409.2M	$-110.74M	$-102.3M
Operating Income / Loss	$-441.59M	$-123.16M	$-112.33M
Cost of Revenue
Net Cash Flow	$-15.85M	$-426.34M	$346.7M
PE Ratio